ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Blood Cancer J. 2021 Sep 21;11(9):157. doi: 10.1038/s41408-021-00541-0.
Blood Cancer J. 2021.
PMID: 34548471
Free PMC article.